Overview

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Status:
Terminated
Trial end date:
2013-02-08
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with relapsed or refractory Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Syndax Pharmaceuticals
Treatments:
Entinostat